Literature DB >> 20421366

Huntington's disease: progress toward effective disease-modifying treatments and a cure.

Carl D Johnson1, Beverly L Davidson.   

Abstract

Huntington's disease (HD) is caused by a dominant mutation in HTT, the HD gene. This discovery opens possibilities for treatment based on silencing of the disease-causing allele or with compounds that reduce the production of disease-causing mRNA and/or protein. Although additional developments are needed related to the delivery of gene silencing and discovery and development of drugs that reduce disease-causing gene products, these treatments are predicted to be effective since they act by reducing the source of toxicity. The identification of therapies that act by blocking toxicity is conceptually more complicated, as this requires an accurate understanding of the cellular location and the specific molecular dysfunctions that cause the phenotypes of HD, which is not yet available. Though challenges remain, significant progress has been made. Effective disease-modifying treatments will soon be tested and may lead to disease-altering therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20421366      PMCID: PMC2875055          DOI: 10.1093/hmg/ddq148

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  37 in total

1.  Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.

Authors:  Andreas Weiss; Corinna Klein; Ben Woodman; Kirupa Sathasivam; Miriam Bibel; Etienne Régulier; Gillian P Bates; Paolo Paganetti
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

2.  Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease.

Authors:  Christian Landles; Kirupa Sathasivam; Andreas Weiss; Ben Woodman; Hilary Moffitt; Steve Finkbeiner; Banghua Sun; Juliette Gafni; Lisa M Ellerby; Yvon Trottier; William G Richards; Alex Osmand; Paolo Paganetti; Gillian P Bates
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

3.  A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference.

Authors:  Maria Stella Lombardi; Leonie Jaspers; Christine Spronkmans; Cinzia Gellera; Franco Taroni; Emilio Di Maria; Stefano Di Donato; William F Kaemmerer
Journal:  Exp Neurol       Date:  2009-03-13       Impact factor: 5.330

4.  Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntington's disease model.

Authors:  Sheng Zhang; Mel B Feany; Sudipta Saraswati; J Troy Littleton; Norbert Perrimon
Journal:  Dis Model Mech       Date:  2009-04-06       Impact factor: 5.758

5.  Longitudinal diffusion tensor imaging in Huntington's Disease.

Authors:  Kurt E Weaver; Todd L Richards; Olivia Liang; Mercy Y Laurino; Ali Samii; Elizabeth H Aylward
Journal:  Exp Neurol       Date:  2009-04       Impact factor: 5.330

6.  Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models.

Authors:  Jack Phan; Miriam A Hickey; Peixiang Zhang; Marie-Francoise Chesselet; Karen Reue
Journal:  Hum Mol Genet       Date:  2009-01-05       Impact factor: 6.150

7.  CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup.

Authors:  Simon C Warby; Alexandre Montpetit; Anna R Hayden; Jeffrey B Carroll; Stefanie L Butland; Henk Visscher; Jennifer A Collins; Alicia Semaka; Thomas J Hudson; Michael R Hayden
Journal:  Am J Hum Genet       Date:  2009-02-26       Impact factor: 11.025

8.  Sustained effects of nonallele-specific Huntingtin silencing.

Authors:  Valérie Drouet; Valérie Perrin; Raymonde Hassig; Noëlle Dufour; Gwennaelle Auregan; Sandro Alves; Gilles Bonvento; Emmanuel Brouillet; Ruth Luthi-Carter; Philippe Hantraye; Nicole Déglon
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

9.  Huntington's disease phenocopies are clinically and genetically heterogeneous.

Authors:  Edward J Wild; Ese E Mudanohwo; Mary G Sweeney; Susanne A Schneider; Jon Beck; Kailash P Bhatia; Martin N Rossor; Mary B Davis; Sarah J Tabrizi
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

10.  Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.

Authors:  Michelle Gray; Dyna I Shirasaki; Carlos Cepeda; Véronique M André; Brian Wilburn; Xiao-Hong Lu; Jifang Tao; Irene Yamazaki; Shi-Hua Li; Yi E Sun; Xiao-Jiang Li; Michael S Levine; X William Yang
Journal:  J Neurosci       Date:  2008-06-11       Impact factor: 6.167

View more
  27 in total

Review 1.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

2.  Co-opting endogenous microRNAs for therapy.

Authors:  Christopher E Pearson
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

Review 3.  Genetically engineered livestock for biomedical models.

Authors:  Christopher S Rogers
Journal:  Transgenic Res       Date:  2016-01-28       Impact factor: 2.788

Review 4.  Recent advances in molecular therapies for neurological disease: triplet repeat disorders.

Authors:  Pedro Gonzalez-Alegre
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 5.  [Huntington's disease].

Authors:  J D Rollnik
Journal:  Nervenarzt       Date:  2015-06       Impact factor: 1.214

6.  Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice.

Authors:  Lixiang Ma; Baoyang Hu; Yan Liu; Scott Christopher Vermilyea; Huisheng Liu; Lu Gao; Yan Sun; Xiaoqing Zhang; Su-Chun Zhang
Journal:  Cell Stem Cell       Date:  2012-03-15       Impact factor: 24.633

7.  The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Authors:  A Reiner; D C Lafferty; H B Wang; N Del Mar; Y P Deng
Journal:  Neurobiol Dis       Date:  2012-03-27       Impact factor: 5.996

8.  Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

Authors:  Sara Valdeolivas; Carmen Navarrete; Irene Cantarero; María L Bellido; Eduardo Muñoz; Onintza Sagredo
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 9.  Pluripotent stem cells models for Huntington's disease: prospects and challenges.

Authors:  Richard L Carter; Anthony W S Chan
Journal:  J Genet Genomics       Date:  2012-05-09       Impact factor: 4.275

10.  Allele-specific regulation of mutant Huntingtin by Wig1, a downstream target of p53.

Authors:  Sun-Hong Kim; Neelam Shahani; Byoung-Ii Bae; Juan I Sbodio; Youjin Chung; Kazuhiro Nakaso; Bindu D Paul; Akira Sawa
Journal:  Hum Mol Genet       Date:  2016-05-19       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.